Skip to main content

Mizuho Americas Hires Graig C. Suvannavejh, PhD, as Senior Biopharmaceuticals and Biotechnology Analyst

Written by Customer Service on . Posted in Public Companies.

NEW YORK, Jan. 12, 2022 (GLOBE NEWSWIRE) — Mizuho Americas today announced the hiring of Graig Suvannavejh, PhD, as Managing Director, Senior Biopharmaceuticals and Biotechnology Equity Research Analyst. Suvannavejh joins an experienced, global healthcare equity research team that includes US based Biotechnology Senior Analysts Mara Goldstein and Salim Syed, Biopharmaceuticals and Biotechnology Senior Analyst Vamil Divan and Analyst Uy Ear, Healthcare Services Senior Analyst Ann Hynes, with Barron Willard, Healthcare trader based in NY. The Japan based team includes Pharmaceuticals Analyst Hiroshi Tanaka, Pharmaceuticals and Biotechnology analyst Shinya Tsuzuki, and Medical Technologies and Services Analysts Takahiro Mori and Kazuki Furuyama.

Dr. Suvannavejh will be based in New York and report to Managing Director and Head of US Equity Research, Susan Gilbertson.

Dr. Suvannavejh has over 20 years of experience in healthcare which includes research roles at both bulge bracket and healthcare-dedicated boutique investment banks and corporate experience with operating roles in business development and strategy at top-tier global biopharmaceutical companies, including AbbVie and Biogen. He joins Mizuho from Goldman Sachs, where he successfully built out and led the European biotechnology research franchise there, and was a key player in the firm’s US biopharmaceuticals research efforts.

“Graig has a wealth of sell-side research analyst experience covering all verticals within the biopharma industry, which combined with his academic and industry operational expertise, allows him a unique and comprehensive perspective on the ever evolving biotech industry,” said Gilbertson. “He has the sensibilities of a scientist and the insights of an industry veteran. His expertise should advance Mizuho’s prominence in providing comprehensive financial services to healthcare issuers and investors.”

Dr. Suvannavejh holds a B.S. in Biology and an M.S. in Physiology & Biophysics from Georgetown University, and received his Ph.D. in Neuroscience from Northwestern University.

About Mizuho Americas

Mizuho Americas is a leading provider of a broad range of financial services, including corporate and investment banking, lending, custody, treasury services, research and capital markets solutions. With professionals across the U.S., Canada, and Latin and South America, Mizuho Americas supports corporate clients, institutional investors, and public sector organizations by connecting local markets to a vast global network. To learn more about Mizuho Americas’ business, values, and ethical commitments, and the entities it comprises, visit www.mizuhogroup.com/americas. ​

Mizuho Americas is an integral part of the Japan-based Mizuho Financial Group, Inc. (NYSE: MFG). Mizuho Financial Group is one of the largest financial institutions in the world, offering comprehensive financial and strategic services through its subsidiaries. The group has approximately 900 offices and 60,000 employees worldwide in nearly 40 countries throughout the Americas, EMEA, and Asia. As of December 31, 2020, its total assets were $2.1 trillion. Learn more about Mizuho Financial Group at www.mizuhogroup.com​.

For inquiries, please contact:
Jim Gorman
Director, Media Relations, Mizuho Americas
+1-212-282-3867
jim.gorman@mizuhogroup.com

Laura London
Vice President, Media Relations, Mizuho Americas
+1-212-282-4446
laura.london@mizuhogroup.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.